

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of IL may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. Blue Cross and Blue Shield of IL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT<sup>®</sup> Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

### **Preventive Services Policy**

Policy Number: CPCP006

Version: 1.0

Enterprise Clinical Payment and Coding Policy Committee Approval Date: December 12, 2024

#### Effective Date: January 1, 2025

Definitions

The following acronyms have been utilized throughout this reimbursement policy

| -       | · · ·  |
|---------|--|
| ACIP:   | Advisory Committee on Immunization Practices       |
| CDC:    | Centers for Disease Control and Prevention         |
| FDA:    | United States Food and Drug Administration         |
| HRSA:   | Health Resources and Services Administration       |
| PPACA:  | Patient Protection and Affordable Care Act of 2010 |
| USPSTF: | United States Preventive Services Task Force       |

## Description

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

Section 2713 of the Patient Protection and Affordable Care Act mandates that private health plans provide coverage of preventive services issued by the following agencies: The United States Preventive Services Task Force , the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention , and the Health Resources and Service Administration with respect to women's guidelines and guidelines for infants, children, and adolescents. These services are available at no cost-share when obtained by a member covered under a non-grandfathered plan. This applies to members belonging to individual, small group, large group, and self-insured plans. There is no copay, deductible or coinsurance, even if the individual or family deductible or out-of-pocket maximum has not been met as long as the member utilizes a provider in the plan's network.

Preventive care or preventive medicine refers to measures or services taken to promote health and early detection/prevention of disease(s) and injuries rather than treating them and/or curing them. Preventive care may include, but are not limited to, examinations and screening tests tailored to an individual's age, health, and family history.

PPACA does not mandate that preventive services be covered at no member cost-share when obtained out-ofnetwork. Members that obtain preventive services out of their network will be subject to copay, deductible, and coinsurance.

Grandfathered plans are plans that have been in existence prior to March 23, 2010 and are exempt from the requirement of providing preventive services at no member cost share. Grandfathered plans have the opportunity to elect providing coverage of preventive services at no member cost share but are not required to do so.

The USPSTF applies a letter grade for each of the recommendations that are released. The grade definitions for USPSTF recommendations released after July 2012 are as follows <u>https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions</u>

Following the recommendation of the USPTF coverage of Grade "A" and "B" recommendations is provided at no member cost share for members with a non-grandfathered health plan. The USPTF published recommendations can be found at

https://www.uspreventiveservicestaskforce.org/BrowseRec/Index

| Grade | Definition   |
|-------|--|
| Α     | The USPSTF recommends the service. There is high certainty that the net benefit is substantial.  |
| В     | The USPSTF recommends the service. There is high<br>certainty that the net benefit is moderate or there is<br>moderate certainty that the net benefit is moderate to<br>substantial.   |
| С     | The USPSTF recommends selectively offering or providing<br>this service to individual patients based on professional<br>judgment and patient preferences. There is at least<br>moderate certainty that the net benefit is small.                         |
| D     | The USPSTF recommends against the service. There is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits.  |
| Ι     | The USPSTF concludes that the current evidence is<br>insufficient to assess the balance of benefits and harms of<br>the service. Evidence is lacking, of poor quality, or<br>conflicting, and the balance of benefits and harms cannot<br>be determined. |

The ACIP publishes recommendations on the safe utilization of vaccines. ACIP's recommendations include immunization schedules for children and adolescents as well as adults which can be found at <u>https://www.cdc.gov/vaccines/schedules/hcp/index.html</u>. Travel Immunizations such as, but not limited to, Japanese Encephalitis, Typhoid, Yellow Fever, and Small Pox are excluded from Preventive Service coverage. Other excluded vaccinations include Anthrax, Bacille Calmette Guerin for Tuberculosis (BCG), and Rabies which are not required by PPACA. Immunizations should be administered in accordance with the ACIP Recommended Child and Adult Immunization Schedules or in accordance with state law or regulations.

HRSA releases Women's Preventive Services guidelines that are aimed at improving women's health by recommending certain preventive services that should be obtained in the clinical setting. HRSA's list of recommendations can be obtained at <u>https://www.hrsa.gov/womensguidelines2016/index.html</u>

HRSA endorses preventive guidelines established by the American Academy of Pediatrics for the health and wellbeing of infants, children, and adolescents. These recommendations are referred to as Bright Futures and the comprehensive list of Bright Future's recommendations can be found at <u>https://www.hrsa.gov/womens-</u> <u>guidelines</u>

# **Reimbursement Information**

Certain preventive care services may be considered eligible for coverage under the member's benefit plan as required by PPACA and/or an applicable state mandate. In general, these services include, but are not limited to, screenings, immunizations, and other types of care as recommended by the United States Federal Government.

These services are not subject to application of cost-sharing such as co-payments, co-insurance or deductibles when they are considered eligible for coverage and are provided by a network provider. In order for preventive claims to process at the preventive level with no member cost share, the claim must include a preventive diagnosis code, a preventive procedure code, meet medical policy review criteria, and fall within the guidelines issued by the USPSTF, ACIP, HRSA, or Bright Futures.

Health care providers (facilities, physicians and other health care professionals) are expected to exercise independent medical judgement in providing care to patients. This Preventive Services Reimbursement policy is not intended to impact care decisions or medical practice.

The following grid provides a list of the recommendations released by the USPSTF, ACIP, HRSA, or Bright Futures along with the corresponding procedure codes and diagnosis codes deemed to be preventive.

| USPSTF Recommendations:                   |                      |                                   |
|---|----------------------|-----------------------------------|
| Service:                                  | Procedure Code(s):   | Additional Reimbursement          |
|   |                      | Criteria:                         |
| Abdominal Aortic Aneurysm Screening       | 76706                | Procedure code 76706 is           |
|   |                      | reimbursable as preventive        |
| USPSTF "B" Recommendation December        |                      | when submitted with one of the    |
| <u>2019</u>                               |                      | following: Z13.6, Z87.891, Z72.0, |
| The USPSTF recommends 1-time screening    |                      | Z00.00, Z00.01, F17.210, F17.200  |
| for abdominal aortic aneurysm with        |                      |                                   |
| ultrasonography in men aged 65 to 75      |                      |                                   |
| years who have ever smoked.               |                      |                                   |
| Unhealthy Alcohol Use in Adolescents      | 99385, 99386, 99387, | Payable with a diagnosis code in  |
| and                                       | 99395, 99396,        | Diagnosis List 1.                 |
| Adults: Screening and Behavioral          | 99397, 99408,        |                                   |
| Counseling                                | 99409, G0396,        |                                   |
| Interventions                             | G0397, G0442,        |                                   |
|   | G0443                |                                   |
| USPSTF "B" Recommendation November        |                      |                                   |
| <u>2018</u>                               |                      |                                   |
| The USPSTF recommends screening for       |                      |                                   |
| unhealthy alcohol use in primary care     |                      |                                   |
| settings for adults 18 years or older,    |                      |                                   |
| including pregnant women, and providing   |                      |                                   |
| persons engaged in risky or hazardous     |                      |                                   |
| drinking with brief behavioral counseling |                      |                                   |

| interventions to reduce unhealthy alcohol |                      |                                |
|---|----------------------|--------------------------------|
| use.                                      |                      |                                |
|   |                      |                                |
| Anxiety Screening Disorders in Adults     | 96127, 99384, 99385, | Procedure code 96127 is only   |
|   | 99386, 99387,        | reimbursable at the preventive |
| USPSTF Released FINAL "B"                 | 99394, 99395,        | level when billed with a       |
| Recommendation for Screening for          | 99396, 99397, G0444  | diagnosis of Z00.129, Z13.31,  |
| Anxiety Disorders in Adults 06/30/2023    |                      | Z13.32, Z13.39, Z13.41, or     |
|   |                      | Z13.42                         |
| The USPSTF recommends screening for       |                      |                                |
| anxiety disorders in adults, including    |                      |                                |
| pregnant and postpartum persons.          |                      |                                |
| Aspirin Use to Prevent Preeclampsia and   |                      | For details about pharmacy     |
| Related Morbidity and Mortality:          |                      | benefit coverage, contact the  |
| Preventive                                |                      | number on the patient's BCBS   |
| Medication                                |                      | member card. A patient's       |
|   |                      | pharmacy benefit may be        |
| USPSTF "B" Recommendation September       |                      | managed by a company other     |
| <u>2021</u>                               |                      | than BCBS.                     |
| The USPSTF recommends the use of low-     |                      |                                |
| dose aspirin (81 mg/day) as preventive    |                      | Coverage includes generic      |
| medication after 12 weeks of gestation in |                      | aspirin 81 mg tablets with a   |
| persons who are at high risk for          |                      | prescription.                  |
| preeclampsia.                             |                      |                                |
| Asymptomatic Bacteriuria in Adults        | 81007, 87086, 87088  | Payable with a Pregnancy       |
| Screening                                 |                      | Diagnosis                      |
|   |                      |                                |
| USPSTF "B" Recommendation September       |                      |                                |
| <u>2019</u>                               |                      |                                |
| The USPSTF recommends screening for       |                      |                                |
| asymptomatic bacteriuria using urine      |                      |                                |
| culture in pregnant persons.              |                      |                                |

| BRCA-Related Cancer Risk Assessment,         | 81212, 81215, 81216, | These services are subject to    |
|--|----------------------|----------------------------------|
| Genetic Testing                              | 81217, 81162,        | Medical Policy and prior         |
|  | 81163, 81164,        | authorization may be required.   |
| USPSTF "B" Recommendation August             | 81165, 81166,        | Procedure codes 81212, 81215-    |
| 2019   | 81167, 96040,        | 81217, 81162-81167, 81307 and    |
| USPSTF recommends that primary care          | 99385, 99386,        | 81308 are reimbursable as        |
|  |                      | preventive when submitted with   |
| clinicians assess women with a personal or   | 99387, 99395,        | · ·                              |
| family history of breast, ovarian, tubal, or | 99396, 99397,        | one of the following primary     |
| peritoneal cancer or who have an ancestry    | 99401, 99402,        | diagnosis codes:                 |
| associated with breast cancer                | 99403, 99404,        | Z80.3, Z80.41, Z85.3, Z85.43     |
| susceptibility 1 and 2 (BRCA1/2) gene        | G0463, S0265,        |                                  |
| mutations with an appropriate brief          | 81307, 81308         | Procedure code 96040 is          |
| familial risk assessment tool. Women with    |                      | reimbursable as preventive       |
| a positive result on the risk assessment     |                      | when submitted with one of the   |
| tool should receive genetic counseling       |                      | following primary diagnosis      |
| and, if indicated after counseling, genetic  |                      | codes: Z80.3 or Z80.41           |
| testing.                                     |                      |                                  |
|  |                      | All other procedure codes for    |
|  |                      | BRCA are payable with a          |
|  |                      | diagnosis in Diagnosis List 1    |
| Breast Cancer Medications for Risk           |                      | For details about pharmacy       |
| Reduction                                    |                      | benefit coverage, contact the    |
|  |                      | number on the patient's BCBS     |
| USPSTF "B" Recommendations September         |                      | member card. A patient's         |
| <u>2019</u>                                  |                      | pharmacy benefit may be          |
| The USPSTF recommends that clinicians        |                      | managed by a company other       |
| offer to prescribe risk-reducing             |                      | than BCBS.                       |
| medications, such as tamoxifen,              |                      |                                  |
| raloxifene, or aromatase inhibitors, to      |                      | Coverage includes generic        |
| women who are at increased risk for          |                      | anastrozole 1 mg, raloxifene hcl |
| breast cancer and at low risk for adverse    |                      | 60 mg, and tamoxifen citrate 10  |
| medication effects.                          |                      | and 20 mg tablets when used for  |
|  |                      | prevention in members ages 35    |
|  |                      | and over with a prescription.    |
|  |                      |                                  |

| Breast Cancer Screening                  | 77061, 77062, 77063, | Payable with a diagnosis code in   |
|--|----------------------|------------------------------------|
|  | 77067                | Diagnosis List 1                   |
| USPSTF "B" Recommendation January        |                      |                                    |
| <u>2016</u>                              |                      |                                    |
| The USPSTF recommends biennial           |                      |                                    |
| screening mammography for women aged     |                      |                                    |
| 40-to 74 years.                          |                      |                                    |
|  |                      |                                    |
| Refer also to HRSA's 'Breast Cancer      |                      |                                    |
| Screening for Women at Average Risk'     |                      |                                    |
| recommendation.                          |                      |                                    |
| Breastfeeding Primary Care Interventions | 99401, 99402, 99403, | Electric breast pumps limited to   |
|  | 99404, 99411,        | one per benefit period. Hospital   |
| USPSTF "B" Recommendation October        | 99412, 99347,        | Grade breast pumps are limited     |
| 2016                                     | 99348, 99349,        | to rental only.                    |
| The USPSTF recommends providing          | 99350, 98960,        |                                    |
| interventions during pregnancy and after | 98961, 98962.        | Additional reimbursement           |
| birth to support breastfeeding.          | G0513, G0514         | information available within the   |
|  |                      | "Breastfeeding Equipment and       |
| Refer also to HRSA's 'Breastfeeding      | A4281, A4282,        | Supplies"                          |
| Services and Supplies' recommendation    | A4283, A4284,        |                                    |
|  | A4285, A4286,        | G0513 & G0514 are payable with     |
|  | E0602, E0603, E0604, | a diagnosis code in Diagnosis List |
|  | S9443, A4287         | 1                                  |
|  |                      |                                    |
|  |                      | Non-physician provider types       |
|  |                      | such as Certified Lactation        |
|  |                      | Counselors and International       |
|  |                      | Board-Certified Lactation          |
|  |                      | Consultants will only be eligible  |
|  |                      | for reimbursement for the          |
|  |                      | following codes: S9443, 98960,     |
|  |                      | 98961, 98962.                      |

| Cervical Cancer Screening                   | 99385, 99386, 99387, | Payable with a diagnosis code in |
|---|----------------------|----------------------------------|
|   | 99395, 99396,99397   | Diagnosis List 1                 |
| USPSTF "A" Recommendation August            |                      |                                  |
| 2018  | G0101, 88141,        |                                  |
| The USPSTF recommends screening for         | 88142, 88143,        |                                  |
| cervical cancer every 3 years with cervical | 88147, 88148,        |                                  |
| cytology alone in women aged 21 to 29       | 88150, 88152,        |                                  |
| years. For women aged 30 to 65 years, the   | 88153, 88155,        |                                  |
| USPSTF recommends screening every 3         | 88164, 88165,        |                                  |
| years with cervical cytology alone, every 5 | 88166, 88167,        |                                  |
| years with high-risk human papillomavirus   | 88174, 88175,        |                                  |
| (hrHPV) testing alone, or every 5 years     | G0123, G0124,        |                                  |
| with hrHPV testing in combination with      | G0141, G0143,        |                                  |
| cytology (cotesting).                       | G0144, G0145,        |                                  |
|   | G0147, G0148,        |                                  |
| Refer also to HRSA's 'Cervical Cancer       | P3000, P3001,        |                                  |
| Screening' recommendation.                  | Q0091, 87623,        |                                  |
|   | 87624, 87625, S0610, |                                  |
|   | S0612, 0500T,0096U,  |                                  |
| Chlamydia Screening                         | 86631, 86632, 87110, | Payable with a diagnosis code in |
|   | 87270, 87320,        | Diagnosis List 1                 |
| USPSTF "B" Recommendations September        | 87490, 87491,        |                                  |
| 2021  | 87492, 87801, 87810  |                                  |
| The USPSTF recommends screening for         |                      |                                  |
| chlamydia in sexually active women age      |                      |                                  |
| 24 years and younger and in women 25        |                      |                                  |
| years or older who are at increased risk    |                      |                                  |
| for infection.                              |                      |                                  |

| Colorectal Cancer Screening                | 82270, 82274,        | Certain colorectal cancer          |
|--|----------------------|------------------------------------|
|  | G0328, 44388,        | screening services may be          |
| USPSTF "A" Recommendation May 2021         | 44389,44392, 44394,  | subject to medical policy criteria |
| The USPSTF recommends screening for        | 44401, 44404,        | and may require prior              |
| colorectal cancer in all adults aged 50 to | 45378,45380,         | authorization.                     |
| 75 years.                                  | 45381,45384,         |                                    |
|  | 45385,45388, G0105,  | Modifier 33 or PT may be           |
| USPSTF "B" Recommendation May 2021         | G0121, 45330,        | applied                            |
| The USPSTF recommends screening for        | 45331, 45333,45335,  |                                    |
| colorectal cancer in adults aged 45 to 49  | 45338,45346, 74263,  | Payable with a diagnosis in        |
| years.                                     | 88304, 88305,        | Diagnosis List 1.                  |
| The risks and benefits of different        | G0104, 99202,        |                                    |
| screening methods vary.                    | 99203, 99204,        | In the instance that a polyp is    |
|  | 99205, 99211,        | removed during a preventive        |
|  | 99212, 99213,        | colonoscopy, the colonoscopy as    |
|  | 99214, 99215,        | well as the removal of the polyp   |
|  | 99417, S0285, 00812, | and the labs and services related  |
|  | 00813, 81528         | to the colonoscopy are             |
|  |                      | reimbursable at the preventive     |
|  |                      | level.                             |
|  |                      |                                    |
|  |                      | Sedation procedure codes           |
|  |                      | 99152, 99153, 99156, 99157,        |
|  |                      | and G0500 will process at the      |
|  |                      | preventive level when billed       |
|  |                      | with a diagnosis of Z12.11 or      |
|  |                      | Z12.12.                            |
|  |                      |                                    |
|  |                      | Procedure code 74263 is            |
|  |                      | reimbursable at the preventive     |
|  |                      | level when billed with one of the  |
|  |                      | following three diagnosis codes:   |
|  |                      | 200.00, 212.11, 212.12.            |
|  |                      |                                    |

|  |                     | Procedure code 81528 is<br>reimbursable at the preventive<br>level when billed with Z12.11 or<br>Z12.12 for out of network<br>claims.  |
|--|---------------------|--|
|  |                     | For details about pharmacy<br>benefit coverage, contact the<br>number on the patient's BCBS<br>member card. A patient's<br>pharmacy benefit may be<br>managed by a company other<br>than BCBS.                               |
|  |                     | Coverage includes generic peg<br>3350-kcl-na bicarb-nacl-na<br>sulfate, peg 3350-kcl-nacl-na<br>sulfate-na ascorbate-c, or peg<br>3350-kcl-sod bicarb-nacl<br>solutions for members ages 45<br>and over with a prescription. |
|  |                     | Diagnosis codes R19.5, K63.5,<br>Z86.0100, Z86.0101, Z86.0102,<br>Z86.0109 will pay at the<br>preventive level.  |
| Congenital Hypothyroidism Screening  | 84443, 99381, S3620 |  |
| <u>USPSTF "A" Recommendation March 2008</u><br>The USPSTF recommends screening for<br>congenital hypothyroidism in newborns. |                     |  |
|  |                     | l  |

| Dental Caries in Children from Birth          | 99188                | For details about pharmacy       |
|---|----------------------|----------------------------------|
| Through Age 5 Years Screening                 | 99100                | benefit coverage, contact the    |
| Through Age 5 Tears Screening                 |                      | number on the patient's BCBS     |
| USPSTF "B" Recommendation December            |                      | member card. A patient's         |
|   |                      | •                                |
| 2021  |                      | pharmacy benefit may be          |
| The USPSTF recommends that primary            |                      | managed by a company other       |
| care clinicians prescribe oral fluoride       |                      | than BCBS.                       |
| supplementation starting at age 6 months      |                      |                                  |
| for children whose water supply is            |                      | Prescription required for both   |
| deficient in fluoride.                        |                      | OTC and prescription             |
|   |                      | medications.                     |
| USPSTF "B" Recommendation December            |                      |                                  |
| 2021  |                      |                                  |
| The USPSTF recommends that primary            |                      |                                  |
| care clinicians apply fluoride varnish to the |                      |                                  |
| primary teeth of all infants and children     |                      |                                  |
| starting at the age of primary tooth          |                      |                                  |
| eruption.                                     |                      |                                  |
| Depression Screening Adults                   | 99385, 99386, 99387, | Payable with a diagnosis code in |
|   | 99395, 99396,        | Diagnosis List 1                 |
| USPSTF "B" Recommendation January             | 99397, 96160,        |                                  |
| 2016  | 96161, G0444, 96127  | Procedure code 96127 is only     |
| The USPSTF recommends screening for           |                      | reimbursable at the preventive   |
| depression in the general adult               |                      | level when billed with a         |
| population, including pregnant and            |                      | diagnosis of Z00.129, Z13.31,    |
| postpartum women. Screening should be         |                      | Z13.32, Z13.39, Z13.41, or       |
| implemented with adequate systems in          |                      | Z13.42                           |
| place to ensure accurate diagnosis,           |                      |                                  |
| effective treatment, and appropriate          |                      |                                  |
| follow-up.                                    |                      |                                  |
|   |                      |                                  |
|   |                      |                                  |
| USPSTF Released FINAL "B"                     |                      |                                  |
| Recommendation for Screening for              |                      |                                  |
| Depression and Suicide Risk in Adults         |                      |                                  |
| Suicide Risk is an "I" recommendation         |                      |                                  |
| which does not apply to the CPCP.             |                      |                                  |

| Depression in Children and Adolescents        | 99384, 99385, 99394, | Payable with a diagnosis in      |
|---|----------------------|----------------------------------|
| Screening                                     | 99395, 96127, G0444  | Diagnosis List 1 Procedure code  |
|   |                      | 96127 is only reimbursable at    |
| USPSTF "B" Recommendation February            |                      | the preventive level when billed |
| 2016  |                      | with a diagnosis of Z00.129,     |
| The USPSTF recommends screening for           |                      | Z13.31, Z13.32, Z13.39, Z13.41,  |
| major depressive disorder in adolescents      |                      | or Z13.42                        |
| aged 12 to 18 years. Screening should be      |                      |                                  |
| implemented with adequate systems in          |                      |                                  |
| place to ensure accurate diagnosis,           |                      |                                  |
| effective treatment, and appropriate          |                      |                                  |
| follow-up.                                    |                      |                                  |
|   |                      |                                  |
| Refer also to Bright Futures 'Depression      |                      |                                  |
| Screening' recommendation                     |                      |                                  |
| Falls Prevention in Community Dwelling        | 97110, 97112, 97116, | Procedure codes 97110, 97112,    |
| Older Adults: Interventions                   | 97150, 97161,        | 97116, 97150, 97161, 97162,      |
|   | 97162, 97163,        | 97163, 97164, 97165, 97166,      |
| USPSTF "B" Recommendation April 2018          | 97164, 97165,        | 97167, 97168, and 97530          |
| The USPSTF recommends exercise                | 97166, 97167,        | reimbursable with a diagnosis of |
| interventions to prevent falls in             | 97168, 97530         | Z91.81.                          |
| community-dwelling adults aged 65 years       |                      |                                  |
| or older who are at increased risk for falls. |                      |                                  |
| Folic Acid for the Prevention of Neural       |                      | For details about pharmacy       |
| Tube  |                      | benefit coverage, contact the    |
| Defects: Preventive Medication                |                      | number on the patient's BCBS     |
|   |                      | member card. A patient's         |
| USPSTF "A" Recommendation January             |                      | pharmacy benefit may be          |
| 2017  |                      | managed by a company other       |
| The USPSTF recommends that all women          |                      | than BCBS.                       |
| who are planning or capable of pregnancy      |                      |                                  |
| take a daily supplement containing 0.4 to     |                      | Prescription required for both   |
| 0.8 mg (400 to 800 μg) of folic acid.         |                      | OTC and prescription             |
|   |                      | medications.                     |

| Gestational Diabetes: Screening           | 36415, 82947, 82948, | Payable with a pregnancy         |
|---|----------------------|----------------------------------|
| 5   | 82950, 82951,        | diagnosis                        |
| USPSTF "B" Recommendation August          | 82952, 83036         | C                                |
| 2021                                      |                      |                                  |
| The USPSTF recommends screening for       |                      |                                  |
| gestational diabetes in asymptomatic      |                      |                                  |
| pregnant persons at 24 weeks of gestation |                      |                                  |
| or after.                                 |                      |                                  |
|   |                      |                                  |
| Refer also to HRSA's 'Gestational         |                      |                                  |
| Diabetes' recommendation                  |                      |                                  |
| Gonorrhea                                 | 87801, 87590, 87591, | Payable with a diagnosis code in |
|   | 87592, 87850         | Diagnosis List 1                 |
| USPSTF "B" Recommendation September       |                      |                                  |
| <u>2021</u>                               |                      |                                  |
| The USPSTF recommends screening for       |                      |                                  |
| gonorrhea in sexually active women age    |                      |                                  |
| 24 years and younger and in women 25      |                      |                                  |
| years or older who are at increased risk  |                      |                                  |
| for infection.                            |                      |                                  |
| Healthy Diet and Physical Activity for    | 99385, 99386, 99387, |                                  |
| Cardiovascular Disease Prevention in      | 99395, 99396,        |                                  |
| Adults with Cardiovascular Risk Factors:  | 99397, G0438,        |                                  |
| Behavioral Counseling                     | G0439, G0446,        |                                  |
|   | S9452, S9470, 97802, |                                  |
| USPSTF "B" Recommendation November        | 97803, 97804,        |                                  |
| 2020                                      | G0270, G0271,        |                                  |
| The USPSTF recommends offering or         | 99078, 99401,        |                                  |
| referring adults with cardiovascular      | 99402, 99403,        |                                  |
| disease risk factors to behavioral        | 99404, 99411,        |                                  |
| counseling interventions to promote a     | 99412, G0473         |                                  |
| healthy diet and physical activity.       |                      |                                  |
| Healthy Weight and Weight Gain in         | 99384, 99385, 99386, |                                  |
| Pregnancy: Behavioral Counseling          | 99394, 99395,        |                                  |
| Interventions                             | 99396, 99401,        |                                  |
|   | 99402, 99403,        |                                  |
| USPSTF "B" Recommendation May 2021        | 99404, 99411, 99412  |                                  |
| The USPSTF recommends that clinicians     |                      |                                  |
| offer pregnant persons effective          |                      |                                  |
| behavioral counseling interventions aimed |                      |                                  |
| at promoting healthy weight gain and      |                      |                                  |

| preventing excess gestational weight gain    |                      |                                   |
|--|----------------------|-----------------------------------|
| in pregnancy.                                |                      |                                   |
|  |                      |                                   |
| Hepatitis B in Pregnant Women Screening      | 80055, 86704, 86705, | Payable with a pregnancy          |
|  | 86706, 86707,        | diagnosis, or a diagnosis code in |
| USPSTF "A" Recommendation July 2019          | 87340, 87341,        | Diagnosis List 1                  |
| The USPSTF recommends screening for          | 80074, 80076,        |                                   |
| hepatitis B virus infection in pregnant      | G0499, 36415         |                                   |
| women at their first prenatal visit.         |                      |                                   |
| Hepatitis B Virus Infection Screening        | 80055, 80074, 80076, | Payable with a diagnosis code in  |
|  | 86704, 86705,        | Diagnosis List 1                  |
| USPSTF "B" Recommendation December           | 86706, 86707,        |                                   |
| <u>2020</u>                                  | 87340, 87341         |                                   |
| The USPSTF recommends screening for          |                      |                                   |
| hepatitis B virus infection in adolescents   |                      |                                   |
| and adults at increased risk for infection.  |                      |                                   |
| Hepatitis C Screening                        | 86803, 86804, 87520, | Payable with a pregnancy          |
|  | 87521 G0472          | diagnosis, or a diagnosis code in |
| USPSTF "B" Recommendation March 2020         |                      | Diagnosis List 1                  |
| The USPSTF recommends screening for          |                      |                                   |
| hepatitis C virus infection in adults aged   |                      |                                   |
| 18 to 79 years.                              |                      |                                   |
| High Blood Pressure Screening in Adults      | 93784, 93786, 93788, | Procedure codes 93784, 93786,     |
|  | 93790, 99385,        | 93788, 93790, 99473, and 99474    |
| USPSTF "A" Recommendation April 2021         | 99386, 99387,        | are reimbursable at the           |
| The USPSTF recommends screening for          | 99395, 99396,        | preventive level when billed      |
| high blood pressure in adults aged 18        | 99397, 99473, 99474  | with one of the following         |
| years or older. The USPSTF recommends        |                      | diagnosis codes: R03.0, R03.1,    |
| obtaining measurements outside of the        |                      | Z01.30, Z01.31                    |
| clinical setting for diagnostic confirmation |                      |                                   |
| before starting treatment.                   |                      |                                   |

| Human Immunodeficiency Virus (HIV)           | HIV/Creatine Testing | Baseline and monitoring services         |
|--|----------------------|--|
| Infection Prevention Drug Pre-exposure       | 82565, 82570,        | related to PrEP medication are           |
| Prophylaxis (PrEP)                           | 82575, 87534,        | reimbursable at the                      |
|  | 87535, 87536,        | reimbursable at the preventive           |
| USPSTF "A" Recommendation June 2019          | 87537, 87538, 87539  | level. Details about benefit             |
| The USPSTF recommends that clinicians        |                      | coverage contact the number on           |
| offer preexposure prophylaxis (PrEP) with    | Pregnancy:           | the patient's BCBS card.                 |
| effective antiretroviral therapy to persons  | 81025                |  |
| who are at high risk of HIV acquisition. See |                      | For details about pharmacy               |
| the Clinical Considerations section for      | Injection,           | benefit coverage, contact the            |
| information about identification of          | cabotegravir, 1mg,   | number on the patient's BCBS             |
| persons at high risk and selection of        | HIV PrEP:            | member card. A patient's                 |
| effective antiretroviral therapy.            | J0739                | pharmacy benefit may be                  |
|  |                      | managed by a company other               |
| USPSTF "A" Recommendation August             |                      | than BCBS.                               |
| 2023   |                      |  |
| The USPSTF recommends that clinicians        |                      | Coverage includes generic                |
| prescribe preexposure prophylaxis using      |                      | Truvada (emtricitabine/                  |
| effective antiretroviral therapy to persons  |                      | tenofovir disoproxil fumarate)           |
| who are at increased risk of HIV             |                      | 200-300 mg tablets, Apretude             |
| acquisition to decrease the risk of          |                      | (cabotegravir) 600 mg/ 3 mL              |
| acquiring HIV. Injectables are now added.    |                      | intramuscular extended-release           |
|  |                      | suspension, and Descovy                  |
|  |                      | (emtricitabine-tenofovir                 |
|  |                      | alafenamide fumarate) 200-25             |
|  |                      | mg tablets when used for                 |
|  |                      | prevention with a prescription.          |
|  |                      | There is also a 999 day lookback         |
|  |                      | period for other antiretrovirals         |
|  |                      | to confirm use for preexposure           |
|  |                      | prophylaxis. Refer to the                |
|  |                      | member's drug list for coverage details. |
|  |                      | uetalls.                                 |
|  |                      | Diagnosis Codes HIV Related:             |
|  |                      | Z11.4, Z71.7, B20, Z29.81                |
|  |                      | LII.4, L/I./, DLU, LLY.81                |

| Human Immunodeficiency Virus (HIV)Infection Screening for Non-PregnantAdolescents and AdultsUSPSTF "A" Recommendation June 2019The USPSTF recommendation June 2019The USPSTF recommends that cliniciansscreen for HIV infection in adolescents andadults aged 15 to 65 years. Youngeradolescents and older adults who are atincreased risk should also be screened.   | 87389, 87390, 87391,<br>87806, G0432,<br>G0433, G0435   | Payable with a diagnosis code in<br>Diagnosis List 1   |
|---|---|--|
| Refer also to HRSA's 'HIV Screening and<br>Counseling' recommendation<br>Refer also to Bright Future's 'STI/HIV   |   |  |
| Screening' recommendation   |   |  |
| Human Immunodeficiency Virus (HIV)Infection Screening for Pregnant WomenUSPSTF "A" Recommendation June 2019The USPSTF recommends that cliniciansscreen all pregnant persons, , includingthose who present in labor or at deliverywhose HIV status is unknown.Refer also to HRSA's 'HIV Screening andCounseling' recommendationRefer also to Bright Future's 'STI/HIVScreening' recommendation                         | 36415, 80081, 86689,<br>86701, 86702,<br>86703,<br>87389, 87390,<br>87391,<br>87806, G0432,<br>G0433, G0435,<br>G0475 | Payable with a pregnancy<br>diagnosis or a diagnosis code in<br>Diagnosis List 1   |
| Hypertension in Adults: Screening<br><u>USPSTF "A" Recommendation April 2021</u><br>The U.S. Preventive Task Force (USPSTF)<br>recommends screening for hypertension<br>in adults 18 years or older with office<br>blood pressure measurements (OBPM).<br>The USPSTF recommends obtaining blood<br>pressure measurements outside of the<br>clinical setting for diagnostic confirmation<br>before starting treatment. | 93784, 93786, 93788,<br>93790, 99385,<br>99386, 99387,<br>99395, 99396,<br>99397, 99473, 99474                        | Procedure codes 93784, 93786,<br>93788, 93790, 99473, 99474 are<br>payable at no member cost<br>share when billed with the DX<br>codes R03.0, R03.1, Z01.30,<br>Z01.31 |

| Intimate Partner Violence, Elder Abuse,      | 99202, 99203, 99204, | Payable with a diagnosis code in   |
|--|----------------------|------------------------------------|
| and Abuse of Vulnerable Adults               | 99205, 99211,        | Diagnosis List 1                   |
| Screening                                    | 99212, 99213,        |                                    |
|  | 99214, 99215,        |                                    |
| USPSTF "B" Recommendation October            | 99384, 99385,        |                                    |
| 2018   | 99386,99387, 99394,  |                                    |
| The U.S. Preventive Services Task Force      | 99395, 99396,        |                                    |
| (USPSTF) recommends that clinicians          | 99397, 99401,        |                                    |
| screen for intimate partner violence in      | 99402, 99403,        |                                    |
| women of reproductive age and provide        | 99404, 99411,        |                                    |
| or refer women who screen positive to        | 99412, 99417, S0610, |                                    |
| ongoing support services.                    | S0612, S0613         |                                    |
| Latent Tuberculosis Infection Screening      | 86480, 86481, 86580  | Payable with a diagnosis code in   |
|  |                      | Diagnosis List 1                   |
| USPSTF "B" Recommendation September          |                      |                                    |
| 2016   |                      |                                    |
| The USPSTF recommends screening for          |                      |                                    |
| latent tuberculosis infection (LTBI) in      |                      |                                    |
| populations at increased risk.               |                      |                                    |
| Lung Cancer Screening                        | G0296, 71271         | Subject to medical policy criteria |
|  |                      | and may require                    |
| USPSTF "B" Recommendation March 2021         |                      | preauthorization                   |
| The USPSTF recommends annual                 |                      |                                    |
| screening for lung cancer with low-dose      |                      | Eff. 01/01/2021 procedure code     |
| computed tomography (LDCT) in adults         |                      | 71271 is reimbursable at the       |
| aged 50 to 80 years who have a 20 pack-      |                      | preventive level if it meets       |
| year smoking history and currently smoke     |                      | medical policy criteria and is     |
| or have quit within the past 15 years.       |                      | billed with one of the following   |
| Screening should be discontinued once a      |                      | diagnosis codes: F17.200,          |
| person has not smoked for 15 years or        |                      | F17.201, F17.210, F17.211,         |
| develops a health problem that               |                      | F17.220,                           |
| substantially limits life expectancy or the  |                      | F17.221, F17.290, F17.291,         |
| ability or willingness to have curative lung |                      | Z12.2, Z87.891                     |
| surgery.                                     |                      |                                    |

| Weight Loss to Prevent Obesity-Related     | 97802, 97803, 97804, |                             |
|--|----------------------|-----------------------------|
| Morbidity and Mortality in Adults:         | 99385, 99386,        |                             |
| Behavioral Interventions                   | 99387, 99395,        |                             |
|  | 99396, 99397,        |                             |
| USPSTF "B" Recommendation September        | 99401, 99402,        |                             |
| <u>2018</u>                                | 99403, 99404,        |                             |
| The USPSTF recommends that clinicians      | 99411, 99412,        |                             |
| offer or refer adults with a body mass     | 99078, G0447,        |                             |
| index (BMI) of 30 or higher (calculated as | G0473                |                             |
| weight in kilograms divided by height in   |                      |                             |
| meters squared) to intensive,              |                      |                             |
| multicomponent behavioral interventions.   |                      |                             |
| Obesity in Children and Adolescents        | 97802, 97803, 99383, |                             |
| Screening                                  | 99384, 99385,        |                             |
|  | 99393, 99401,        |                             |
| USPSTF "B" Recommendation June 2017        | 99402, 99403,        |                             |
| The USPSTF recommends that clinicians      | 99404, 99411,        |                             |
| screen for obesity in children and         | 99412, G0446,        |                             |
| adolescents 6 years and older and offer    | G0447, G0473         |                             |
| them or refer them to comprehensive,       |                      |                             |
| intensive behavioral interventions to      |                      |                             |
| promote improvement in weight status.      |                      |                             |
| Ocular Prophylaxis for Gonococcal          |                      | When billed under inpatient |
| Ophthalmia Neonatorum Preventive           |                      | medical                     |
| Medication                                 |                      |                             |
|  |                      |                             |
| USPSTF "A" Recommendation January          |                      |                             |
| <u>2019</u>                                |                      |                             |
| The USPSTF recommends prophylactic         |                      |                             |
| ocular topical medication for all newborns |                      |                             |
| to prevent gonococcal ophthalmia           |                      |                             |
| neonatorum.                                |                      |                             |
|  |                      |                             |

| Osteoporosis Screening<br>USPSTF "B" Recommendation June 2018<br>The USPSTF recommends screening for<br>osteoporosis with bone measurement<br>testing to prevent osteoporotic fractures<br>in women 65 years and older.<br>The USPSTF recommends screening for<br>osteoporosis with bone measurement<br>testing to prevent osteoporotic fractures<br>in postmenopausal women younger than<br>65 years who are at increased risk of<br>osteoporosis, as determined by a formal<br>clinical risk assessment tool. | 76977, 77078, 77080,<br>77081, 78350,<br>78351,<br>G0130  | Payable with a diagnosis code in<br>Diagnosis List 1  |
|---|---|---|
| Perinatal Depression: PreventiveInterventionsUSPSTF "B" Recommendation February2019The USPSTF recommends that cliniciansprovide or refer pregnant and postpartumpersons who are at increased risk ofperinatal depression to counselinginterventions.  | 99385,99386, 99387,<br>99395, 99396,<br>99397, 99401,<br>99402, 99403,<br>99404, 96160,<br>96161,<br>G0444  | Payable with a diagnosis code in<br>Diagnosis List 1  |
| Phenylketonuria in Newborns Screening USPSTF "A" Recommendation March 2008 The USPSTF recommends screening for phenylketonuria in newborns.   | 84030, 99381, S3620   | Procedure codes 84030 and<br>S3620 reimbursable at the<br>preventive level for children 0-<br>90 days old |
| Prediabetes and Type 2 DiabetesScreeningUSPSTF "B" Recommendation August2021The USPSTF recommends screening for<br>prediabetes and type 2 diabetes in adults<br>aged 35 to 70 years who have overweight<br>or obesity. Clinicians should offer or refer<br>patients with prediabetes to effective<br>preventive interventions.  | 82947, 82948, 82950,<br>82951, 83036,<br>82952, 97802,<br>97803, 97804,<br>99401, 99402,<br>99403, 99404,<br>G0270, G0271,<br>G0447, G0473, S9470 | Payable with a diagnosis code in<br>Diagnosis List 1  |

| Preeclampsia Screening                      |   | Preeclampsia screening is done     |
|---|---|------------------------------------|
|   |   | through routine blood pressure     |
| USPSTF "B" Recommendation April 2017        |   | measurements                       |
| The USPSTF recommends screening for         |   |                                    |
| preeclampsia in pregnant women with         |   |                                    |
| blood pressure measurements throughout      |   |                                    |
| pregnancy.                                  |   |                                    |
| Rh(D) Incompatibility Screening             | 80055, 86850, 86870,<br>86900, 86901, 36415 | Payable with a pregnancy diagnosis |
| USPSTF "A" Recommendation February          |   |                                    |
| <u>2004</u>                                 |   |                                    |
| The USPSTF strongly recommends Rh(D)        |   |                                    |
| blood typing and antibody testing for all   |   |                                    |
| pregnant women during their first visit for |   |                                    |
| pregnancy-related care.                     |   |                                    |
| USPSTF "B" Recommendation February          |   |                                    |
| <u>2004</u>                                 |   |                                    |
| The USPSTF recommends repeated Rh(D)        |   |                                    |
| antibody testing for all unsensitized       |   |                                    |
| Rh(D)negative women at 24 to 28 weeks'      |   |                                    |
| gestation, unless the biological father is  |   |                                    |
| known to be Rh(D)-negative.                 |   |                                    |
| Sexually Transmitted Infections             | 99384, 99385, 99386,                        |                                    |
| Behavioral                                  | 99387, 99394,                               |                                    |
| Counseling                                  | 99395, 99396,                               |                                    |
|   | 99397, 99401,                               |                                    |
| USPSTF "B" Recommendation August            | 99402, 99403,                               |                                    |
| <u>2020</u>                                 | 99404, 99411,                               |                                    |
| The USPSTF recommends behavioral            | 99412, G0445                                |                                    |
| counseling for all sexually active          |   |                                    |
| adolescents and for adults who are at       |   |                                    |
| increased risk for sexually transmitted     |   |                                    |
| infections (STIs).                          |   |                                    |
| Refer also to HRSA's 'Sexually Transmitted  |   |                                    |
| Infections Counseling' recommendation.      |   |                                    |

|   | 02020 02024 02020             |  |
|---|-------------------------------|--|
| Sickle Cell Disease (Hemoglobinopathies)  | 83020, 83021, 83030,          |  |
| in Newborns Screening   | 83033, 83051,                 |  |
|   | 85004, 85013,                 |  |
| USPSTF "A" Recommendation September   | 85014, 85018,                 |  |
| <u>2007</u>   | 85025, 85027,                 |  |
| The USPSTF recommends screening for   | 99381, G0306,                 |  |
| sickle cell disease in newborns.  | G0307, S3620, S3850           |  |
| Skin Cancer Counseling  | There are no                  |  |
|   | procedure codes               |  |
| USPSTF "B" Recommendation March 2018  | specific to skin              |  |
| The USPSTF recommends counseling  | cancer counseling.            |  |
| young adults, adolescents, children, and  |                               |  |
| parents of young children about   |                               |  |
| minimizing exposure to ultraviolet (UV)   |                               |  |
| radiation for persons aged 6 months to 24   |                               |  |
| years with fair skin types to reduce their  |                               |  |
| risk of skin cancer.  |                               |  |
| Statin Use for the Primary Prevention of  | 80061, 82465, 83700,          | For details about pharmacy   |
| Cardiovascular Disease in Adults  | 83718, 83719,                 | benefit coverage, contact the  |
| Preventive Medication   | 83721, 84478                  | number on the patient's BCBS   |
|   |                               | member card. A patient's   |
| USPSTF "B" Recommendation August  |                               | pharmacy benefit may be  |
| 2022  |                               | managed by a company other   |
| The USPSTF recommends that clinicians   |                               | than BCBS.   |
| prescribe a statin for the primary  |                               |  |
| prevention of CVD for adults aged 40 to 75  |                               | Coverage includes atorvastatin   |
| years who have 1 or more CVD risk factors   |                               | 10 mg,20 mg, 40 mg, and 80 mg,   |
| (i.e. dyslipidemia, diabetes, hypertension,   |                               | lovastatin 20 mg and 40 mg   |
| or smoking) and an estimated 10-year risk   |                               | tablets, pravastatin 10 mg, 20   |
| of a cardiovascular event of 10% or   |                               | mg, 40 mg, and 80 mg tablets for   |
| greater.  |                               | members ages 40 – 75 years of  |
|   |                               | age with a prescription.   |
| Syphilis Infection in Nonpregnant Adults  | 86592, 86780, 0065U           | Payable with a diagnosis code in   |
| and   |                               | Diagnosis List 1   |
| Adolescents Screening   |                               |  |
|   |                               |  |
| USPSTF "A" Recommendation June 2016   |                               |  |
| The USPSTF recommends screening for   |                               |  |
| syphilis infection in persons who are at  |                               |  |
| increased risk for infection.   |                               |  |
| radiation for persons aged 6 months to 24<br>years with fair skin types to reduce their<br>risk of skin cancer.<br>Statin Use for the Primary Prevention of<br>Cardiovascular Disease in Adults<br>Preventive Medication<br>USPSTF "B" Recommendation August<br>2022<br>The USPSTF recommends that clinicians<br>prescribe a statin for the primary<br>prevention of CVD for adults aged 40 to 75<br>years who have 1 or more CVD risk factors<br>(i.e. dyslipidemia, diabetes, hypertension,<br>or smoking) and an estimated 10-year risk<br>of a cardiovascular event of 10% or<br>greater.<br>Syphilis Infection in Nonpregnant Adults<br>and<br>Adolescents Screening<br>USPSTF "A" Recommendation June 2016<br>The USPSTF recommends screening for<br>syphilis infection in persons who are at | 83718, 83719,<br>83721, 84478 | <ul> <li>benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.</li> <li>Coverage includes atorvastatin 10 mg,20 mg, 40 mg, and 80 mg, lovastatin 20 mg and 40 mg tablets, pravastatin 10 mg, 20 mg, 40 mg, and 80 mg tablets for members ages 40 – 75 years of age with a prescription.</li> </ul> |

| Syphilis Infection in Pregnant Women           | 80055, 80081, 86592, | Payable with a pregnancy           |
|--|----------------------|------------------------------------|
| Screening                                      | 86593, 86780,        | diagnosis or a diagnosis code in   |
| Screening                                      | 0065U, 36415         | Diagnosis List 1                   |
| LISPSTE "A" Becommendation Sontember           | 00050, 50415         | Diagnosis List 1                   |
| USPSTF "A" Recommendation September            |                      |                                    |
| 2018<br>The UCDCTE recommends confu correction |                      |                                    |
| The USPSTF recommends early screening          |                      |                                    |
| for syphilis infection in all pregnant         |                      |                                    |
| women.   |                      |                                    |
| Tobacco Smoking Cessation in Adults,           | 99401, 99402, 99403, | For details about pharmacy         |
| Including Pregnant Women: Behavioral           | 99404, 99406,        | benefit coverage, contact the      |
| and Pharmacotherapy Interventions              | 99407, G9016, S9453  | number on the patient's BCBS       |
|  |                      | member card. A patient's           |
| USPSTF "A" Recommendation January              |                      | pharmacy benefit may be            |
| <u>2021</u>                                    |                      | managed by a company other         |
| The USPSTF recommends that clinicians          |                      | than BCBS.                         |
| ask all adults about tobacco use, advise       |                      |                                    |
| them to stop using tobacco, and provide        |                      | Two 90-day treatment regimens      |
| behavioral interventions and U.S. Food         |                      | per benefit period. The 90-day     |
| and Drug Administration (FDA)–approved         |                      | treatments are at the discretion   |
| pharmacotherapy for cessation to adults        |                      | of the provider working with the   |
| who use tobacco.                               |                      | member.                            |
|  |                      |                                    |
| USPSTF "A" Recommendation January              |                      | Prescription required for both     |
| 2021   |                      | OTC and prescription               |
| The USPSTF recommends that clinicians          |                      | medications.                       |
| ask all pregnant women about tobacco           |                      |                                    |
| use, advise them to stop using tobacco,        |                      | Coverage includes:                 |
| and provide behavioral interventions for       |                      | Generic bupropion hcl              |
| cessation to pregnant women who use            |                      | (smoking deterrent) ER 12hr 150    |
| tobacco.                                       |                      | mg tablets                         |
|  |                      | Generic nicotine polacrilex 2      |
|  |                      | mg and 4 mg gum                    |
|  |                      | Generic nicotine polacrilex 2      |
|  |                      | mg and 4 mg lozenges               |
|  |                      | • Generic nicotine 24hr 7 mg, 14   |
|  |                      | mg, and 21 mg transdermal          |
|  |                      | patches                            |
|  |                      | • Generic varenicline tartrate 0.5 |
|  |                      | mg and 1 mg tablets                |
|  |                      | Brand Nicotine Transdermal         |
|  |                      | Systems                            |
|  |                      | Brand Nicotrol Inhaler             |
|  |                      | Brand Nicotrol Nasal Spray         |
|  |                      | Brand Meotron Masar Spray          |

| Tobacco Use in Children and Adolescents     | 99401, 99402, 99403, | Refer to Preventive Services     |
|---|----------------------|----------------------------------|
| Primary Care Interventions                  | 99404, 99406,        | Recommendation for Tobacco       |
|   | 99407, G9016, S9453  | Smoking Cessation in Adults,     |
| USPSTF "B" Recommendation April 2020        |                      | Including Pregnant Women:        |
| The USPSTF recommends that primary          |                      | Behavioral and                   |
| care clinicians provide interventions,      |                      | Pharmacotherapy Interventions    |
| including education or brief counseling, to |                      |                                  |
| prevent initiation of tobacco use among     |                      |                                  |
| school-aged children and adolescents.       |                      |                                  |
| Screening for Unhealthy Drug Use            | 99385, 99386, 99387, | Payable with a diagnosis code in |
|   | 99395, 99396,        | Diagnosis List 1                 |
| USPSTF "B" Recommendation June 2020         | 99397, 99408,        |                                  |
| The USPSTF recommends screening by          | 99409, G0396,        |                                  |
| asking questions about unhealthy drug       | G0397                |                                  |
| use in adults age 18 years or older.        |                      |                                  |
| Screening should be implemented when        |                      |                                  |
| services for accurate diagnosis, effective  |                      |                                  |
| treatment, and appropriate care can be      |                      |                                  |
| offered or referred.                        |                      |                                  |
| Vision Screening in Children                | 99172, 99173, 0333T  |                                  |
| USPSTF "B" Recommendation September         |                      |                                  |
| <u>2017</u>                                 |                      |                                  |
| The USPSTF recommends vision screening      |                      |                                  |
| at least once in all children aged 3 to 5   |                      |                                  |
| years to detect amblyopia or its risk       |                      |                                  |
| factors.                                    |                      |                                  |
| General Lab Panel                           | 80050, 80053         | Payable with a diagnosis code in |
|   |                      | Diagnosis List 1                 |
| These lab codes could be multiple           |                      |                                  |
| Preventive Services                         |                      |                                  |
| recommendations.                            |                      |                                  |
|   |                      |                                  |
|   | T                    | Ι                                |
| HRSA Recommendations:                       |                      |                                  |
| Service:                                    | Procedure Code(s):   | Additional Reimbursement         |
|   |                      | Criteria:                        |

| Anxiety Screening                           | 96127, 99384, 99385, | Procedure code 96127 is only        |
|---|----------------------|-------------------------------------|
|   | 99386, 99387,        | ,<br>reimbursable at the preventive |
| HRSA Recommendation December 2019           | 99394, 99395,        | level when billed with a            |
| The Women's Preventive Services             | 99396, 99397, G0444  | diagnosis of Z00.129, Z13.31,       |
| Initiative recommends screening for         |                      | Z13.32, Z13.39, Z13.41, or          |
| anxiety in adolescent and adult women,      |                      | Z13.42                              |
| including those who are pregnant or         |                      |                                     |
| postpartum.                                 |                      |                                     |
| Breast Cancer Screening for Women at        | 77061, 77062, 77063, | Payable with a diagnosis code in    |
| Average Risk                                | 77065, 77066,        | Diagnosis List 1                    |
|   | 77067, G0279         |                                     |
| HRSA Recommendation December 2019           |                      |                                     |
| The Women's Preventive Services             |                      |                                     |
| Initiative recommends that average-risk     |                      |                                     |
| women initiate mammography screening        |                      |                                     |
| no earlier than age 40 and no later than    |                      |                                     |
| age 50. Screening mammography should        |                      |                                     |
| occur at least biennially and as frequently |                      |                                     |
| as annually. Screening should continue      |                      |                                     |
| through at least age 74 and age alone       |                      |                                     |
| should not be the basis to discontinue      |                      |                                     |
| screening. These screening                  |                      |                                     |
| recommendations are for women at            |                      |                                     |
| average risk of breast cancer. Women at     |                      |                                     |
| increased risk should also undergo          |                      |                                     |
| periodic mammography screening,             |                      |                                     |
| however, recommendations for additional     |                      |                                     |
| services are beyond the scope of this       |                      |                                     |
| recommendation                              |                      |                                     |
| Refer also to USPSTF's 'Breast Cancer       |                      |                                     |
| Screening' recommendation.                  |                      |                                     |

| Breastfeeding Services and Supplies         | E0602, E0603, E0604, | Electric breast pumps limited to   |
|---|----------------------|------------------------------------|
|   | A4281, A4282,        | one per benefit period. Hospital   |
| HRSA Recommendation December 2021           | A4283, A4284,        | Grade breast pumps are limited     |
| Women's Preventive Services Initiative      | A4285, A4286,        | to rental only.                    |
| recommends comprehensive lactation          | A4287, G0513,        |                                    |
| support services (including consultation;   | G0514, S9443,        | G0513 & G0514 are payable with     |
| counseling; education by clinicians and     | 99401, 99402,        | a diagnosis code in Diagnosis List |
| peer support services; and breastfeeding    | 99403, 99404,        | 1                                  |
| equipment and supplies) during the          | 99411, 99412,        |                                    |
| antenatal, perinatal, and postpartum        | 99347, 99348,        | Additional reimbursement           |
| periods to optimize the successful          | 99349, 99350,        | information available within the   |
| initiation and maintenance of               | 98960, 98961, 98962  | "Breastfeeding Equipment and       |
| breastfeeding.                              |                      | Supplies" Coverage                 |
|   |                      |                                    |
| Breastfeeding equipment and supplies        |                      | Non-physician provider types       |
| include, but are not limited to, double     |                      | such as Certified Lactation        |
| electric breast pumps (including pump       |                      | Counselors and International       |
| parts and maintenance) and breast milk      |                      | Board-Certified Lactation          |
| storage supplies. Access to double electric |                      | Consultants will only be eligible  |
| pumps should be a priority to optimize      |                      | for reimbursement for the          |
| breastfeeding and should not be             |                      | following codes: S9443, 98960,     |
| predicated on prior failure of a manual     |                      | 98961, 98962.                      |
| pump. Breastfeeding equipment may also      |                      |                                    |
| include equipment and supplies as           |                      |                                    |
| clinically indicated to support dyads with  |                      |                                    |
| breastfeeding difficulties and those who    |                      |                                    |
| need additional services.                   |                      |                                    |
| Refer also to USPSTF's 'Breastfeeding       |                      |                                    |
| Primary                                     |                      |                                    |
| Care Interventions' recommendation.         |                      |                                    |

| Cervical Cancer Screening                    | 0096U, 0500T,       | Payable with a diagnosis code in |
|--|---------------------|----------------------------------|
|  | 87623, 87624,       | Diagnosis List 1                 |
| HRSA Recommendation December 2019            | 87625, 88141,       |                                  |
| The Women's Preventive Services              | 88142, 88143,       |                                  |
| Initiative recommends cervical cancer        | 88147, 88148,       |                                  |
| screening for average-risk women aged 21     | 88150, 88152,       |                                  |
| to 65 years. For women aged 21 to 29         | 88153, 88155,       |                                  |
| years, the Women's Preventive Services       | 88164, 88165,       |                                  |
| Initiative recommends cervical cancer        | 88166, 88167,       |                                  |
| screening using cervical cytology (Pap test) | 88174, 88175,       |                                  |
| every 3 years. Cotesting with cytology and   | 99385, 99386,       |                                  |
| human papillomavirus testing is not          | 99387, 99395,       |                                  |
| recommended for women younger than           | 99396, 99397,       |                                  |
| 30 years. Women aged 30 to 65 years          | G0101, G0123,       |                                  |
| should be screened with cytology and         | G0124, G0141,       |                                  |
| human papillomavirus testing every 5         | G0143, G0144,       |                                  |
| years or cytology alone every 3 years.       | G0145, G0147,       |                                  |
| Women who are at average risk should         | G0148, G0476,       |                                  |
| not be screened more than once every 3       | P3000, P3001,       |                                  |
| years.                                       | Q0091, S0610, S0612 |                                  |
| Refer also to USPSTF 'Cervical Cancer        |                     |                                  |
| Screening' recommendation.                   |                     |                                  |
|  |                     |                                  |

| Contraceptive Methods and Counseling         | 57170, 58300, 58301, | Contraception methods that         |
|--|----------------------|------------------------------------|
| •  | 58600, 58605,        | require a prescription may be      |
| HRSA Recommendation December 2021            | 58611, 58615,        | covered under the patient's        |
| Women's Preventive Services Initiative       | 58661, 58565,        | medical or pharmacy benefit.       |
| recommends that adolescent and adult         | 58670, 58671,        | For details about pharmacy         |
| women have access to the full range of       | 58340, 58700,        | benefit coverage for               |
| contraceptives and contraceptive care to     | 74740, 88302,        | contraception, contact the         |
| prevent unintended pregnancies and           | 88305, 96372,        | number on the patient's BCBS       |
| improve birth outcomes. Contraceptive        | 11976, 11981,        | member card. A patient's           |
| care includes screening, education,          | 11982, 11983,        | pharmacy benefit may be            |
| counseling, and provision of                 | A4261, A4264,        | managed by a company other         |
| contraceptives (including in the             | A4266, A4268,        | than BCBS.                         |
| immediate postpartum period).                | A4269, A9293, J1050, |                                    |
| Contraceptive                                | J7296, J7297, J7298, | Visits pertaining to contraceptive |
| care also includes follow-up care (e.g.,     | J7300, J7301, J7303, | counseling, initiation of          |
| management, evaluation and changes,          | J7304, J7306, J7307, | contraceptive use, and follow-up   |
| including the removal, continuation, and     | A4267, S4981, S4989  | care may also apply to             |
| discontinuation of contraceptives).          |                      | procedure codes under HRSA's       |
|  |                      | 'Well-Woman'                       |
| Women's Preventive Services Initiative       |                      | recommendation                     |
| recommends that the full range of U.S.       |                      |                                    |
| Food and Drug Administration (FDA)-          |                      | Procedure code 58340               |
| approved, granted, or -cleared               |                      | reimbursable at the preventive     |
| contraceptives, effective family planning    |                      | level only when accompanied        |
| practices, and sterilization procedures be   |                      | with modifier 33 or one of the     |
| available as part of contraceptive care.     |                      | following diagnosis codes: Z30.2,  |
|  |                      | Z30.40, Z30.42, Z30.49, Z98.51,    |
| The full range of contraceptives includes    |                      |                                    |
| those currently listed in the FDA's Birth    |                      | Procedure codes 11981, 11982,      |
| Control Guide: (1) sterilization surgery for |                      | and 11983 (are covered only        |
| women, (2) implantable rods, (3) copper      |                      | when FDA approved                  |
| intrauterine devices, (4) intrauterine       |                      | contraceptive implant insertion    |
| devices with progestin (all durations and    |                      | or removal are performed) are      |
| doses), (5) injectable contraceptives, (6)   |                      | reimbursable at the preventive     |
| oral contraceptives (combined pill), 7) oral |                      | level when                         |
| contraceptives (progestin only),             |                      |                                    |
|  |                      |                                    |

(8) oral contraceptives (extended or continuous use), (9) the contraceptive patch, (10) vaginal contraceptive rings, (11) diaphragms, (12) contraceptive sponges, (13) cervical caps, (14) condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), and any additional contraceptives approved, granted, or cleared by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided for women desiring an alternative method. condoms, (15) spermicides, (16) emergency contraception (levonorgestrel), and (17) emergency contraception (ulipristal acetate), and any additional contraceptives approved, granted, or cleared by the FDA. Additionally, instruction in fertility awareness-based methods, including the lactation amenorrhea method, although less effective, should be provided for women desiring an alternative method.

billed with one of the following diagnosis codes: Z30.013, Z30.017, Z30.018, Z30.019, Z30.09, Z30.40, Z30.42, Z30.46, Z30.49, Z30.8, Z30.9 Procedure codes 58661, 58700 reimbursable at the preventive level with a diagnosis of Z30.2

For details about pharmacy benefit coverage, contact the number on the patient's BCBS member card. A patient's pharmacy benefit may be managed by a company other than BCBS.

Prescription required for both OTC and prescription medications. For the list of contraceptive methods that may be covered, visit your health plan website.

Procedure code 96372 payable with a diagnosis code in Diagnosis list 1

| Diabetes Screening after Pregnancy              | 82947, 82948, 82950, | Payable with a diagnosis code in |
|---|----------------------|----------------------------------|
|   | 82951, 83036         | Diagnosis List 1                 |
| HRSA Recommendation December 2019               |                      |                                  |
| The Women's Preventive Services                 |                      |                                  |
| Initiative recommends women with a              |                      |                                  |
| history of gestational diabetes mellitus        |                      |                                  |
| (GDM) who are not currently pregnant            |                      |                                  |
| and who have not been previously                |                      |                                  |
| diagnosed with type 2 diabetes mellitus         |                      |                                  |
| should be screened for diabetes mellitus.       |                      |                                  |
| Initial testing should ideally occur within     |                      |                                  |
| the first year postpartum and can be            |                      |                                  |
| conducted as early as 4–6 weeks                 |                      |                                  |
| postpartum. Women with a negative               |                      |                                  |
| initial postpartum screening test result        |                      |                                  |
| should be rescreened at least every 3           |                      |                                  |
| years for a minimum of 10 years after           |                      |                                  |
| pregnancy. For women with a positive            |                      |                                  |
| postpartum screening test result, testing       |                      |                                  |
| to confirm the diagnosis of diabetes is         |                      |                                  |
| indicated regardless of the initial test (e.g., |                      |                                  |
| oral glucose tolerance test, fasting plasma     |                      |                                  |
| glucose, or hemoglobin A1c). Repeat             |                      |                                  |
| testing is indicated in women who were          |                      |                                  |
| screened with hemoglobin A1c in the first       |                      |                                  |
| 6 months postpartum regardless of the           |                      |                                  |
| result.   |                      |                                  |

| Gestational Diabetes                          | 82947, 82948, 82950, | Payable with a pregnancy |
|---|----------------------|--------------------------|
|   | 82951, 83036         | diagnosis                |
| HRSA Recommendation December 2019             |                      |                          |
| The Women's Preventive Services               |                      |                          |
| Initiative recommends screening pregnant      |                      |                          |
| women for gestational diabetes mellitus       |                      |                          |
| after 24 weeks of gestation (preferably       |                      |                          |
| between 24 and 28 weeks of gestation) in      |                      |                          |
| order to prevent adverse birth outcomes.      |                      |                          |
| Screening with a 50 g oral glucose            |                      |                          |
| challenge test (followed by a 3hour 100 g     |                      |                          |
| oral glucose tolerance test if results on the |                      |                          |
| initial oral glucose challenge test are       |                      |                          |
| abnormal) is preferred because of its high    |                      |                          |
| sensitivity and specificity. The Women's      |                      |                          |
| Preventive Services Initiative suggests that  |                      |                          |
| women with risk factors for diabetes          |                      |                          |
| mellitus be screened for preexisting          |                      |                          |
| diabetes before 24 weeks of gestation—        |                      |                          |
| ideally at the first prenatal visit, based on |                      |                          |
| current clinical best practices.              |                      |                          |
|   |                      |                          |
| Refer also to USPSTF's 'Gestational           |                      |                          |
| Diabetes                                      |                      |                          |
| Mellitus Screening' recommendation.           |                      |                          |

| Human Immune-Deficiency Virus               | 36415, 86689, 86701, | Payable when billed with a     |
|---|----------------------|--------------------------------|
| Counseling & Screening                      | 86702, 86703,        | diagnosis code in on Diagnosis |
|   | 87389, 87390,        | List 1                         |
| HRSA Recommendation December 2021           | 87391, 87806,        |                                |
| Women's Preventive Services Initiative      | G0432, G0433,        |                                |
| recommends all adolescent and adult         | G0435, G0475         |                                |
| women, ages 15 and older, receive a         | 00455, 00475         |                                |
| screening test for HIV at least once during |                      |                                |
| their lifetime. Earlier or additional       |                      |                                |
| screening should be based on risk, and      |                      |                                |
| rescreening annually or more often may      |                      |                                |
| be appropriate beginning at age 13 for      |                      |                                |
| adolescent and adult women with an          |                      |                                |
| increased risk of HIV infection.            |                      |                                |
|   |                      |                                |
| Women's Preventive Services Initiative      |                      |                                |
| recommends risk assessment and              |                      |                                |
| prevention education for HIV infection      |                      |                                |
| beginning at age 13 and continuing as       |                      |                                |
| determined by risk.                         |                      |                                |
| determined by fisk.                         |                      |                                |
| A screening test for HIV is recommended     |                      |                                |
| for all pregnant women upon initiation of   |                      |                                |
| prenatal care with rescreening during       |                      |                                |
| pregnancy based on risk factors. Rapid HIV  |                      |                                |
| testing is recommended for pregnant         |                      |                                |
| women who present in active labor with      |                      |                                |
| an undocumented HIV status. Screening       |                      |                                |
| during pregnancy enables prevention of      |                      |                                |
| vertical transmission.                      |                      |                                |
|   |                      |                                |
| Refer also to USPSTF's 'Human               |                      |                                |
| Immunodeficiency Virus (HIV) Infection      |                      |                                |
| Screening for Pregnant and Non-Pregnant     |                      |                                |
| Adolescents and Adults' recommendation.     |                      |                                |
| Refer also to Bright Future's 'STI/HIV'     |                      |                                |
| Screening' recommendations.                 |                      |                                |

| Interpersonal and Domestic Violence          | 99401, 99402, 99403, | Payable when billed with a       |
|--|----------------------|----------------------------------|
| Screening                                    | 99404, 99411,        | diagnosis code on Diagnosis List |
|  | 99412, 99384,        | 1                                |
| HRSA Recommendation December 2019            | 99385, 99386,        | -                                |
| The Women's Preventive Services              | 99387, 99394,        |                                  |
| Initiative recommends screening              | 99395, 99396,        |                                  |
| adolescents and women for interpersonal      | 99397, 99202,        |                                  |
| and domestic violence at least annually,     | 99203, 99204,        |                                  |
| and, when needed, providing or referring     | 99205, 99211,        |                                  |
| for initial intervention services.           | 99212, 99213,        |                                  |
| Interpersonal and domestic violence          | 99214, 99215, 99417  |                                  |
| includes physical violence, sexual violence, |                      |                                  |
| stalking and psychological aggression        |                      |                                  |
| (including coercion), reproductive           |                      |                                  |
| coercion, neglect, and the threat of         |                      |                                  |
| violence, abuse, or both. Intervention       |                      |                                  |
| services include, but are not limited to,    |                      |                                  |
| counseling, education, harm reduction        |                      |                                  |
| strategies, and referral to appropriate      |                      |                                  |
| supportive services.                         |                      |                                  |
| <b>Obesity Prevention in Midlife Women</b>   | 97802, 97803, 97804, | Payable when billed with a       |
|  | 99078, 99386,        | diagnosis code in on Diagnosis   |
| HRSA Recommendation December 2021            | 99396, 99401,        | List 1                           |
| Women's Preventive Services Initiative       | 99402, 99403,        |                                  |
| recommends counseling midlife women          | 99404, 99411,        |                                  |
| aged 40 to 60 years with normal or           | 99412, G0447,        |                                  |
| overweight body mass index (BMI) (18.5-      | G0473                |                                  |
| 29.9 kg/m2) to maintain weight or limit      |                      |                                  |
| weight gain to prevent obesity. Counseling   |                      |                                  |
| may include individualized discussion of     |                      |                                  |
| healthy eating and physical activity.        |                      |                                  |

| Sexually Transmitted Infections             | 99401, 99402, 99403, |
|---|----------------------|
| Counseling                                  | 99404, 99411,        |
|   | 99412, 99384,        |
| HRSA Recommendation December 2021           | 99385, 99386,        |
| Women's Preventive Services Initiative      | 99387, 99394,        |
| recommends directed behavioral              | 99395, 99396,        |
| counseling by a health care clinician or    | 99397, G0445         |
| other appropriately trained individual for  |                      |
| sexually active adolescent and adult        |                      |
| women at an increased risk for STIs.        |                      |
|   |                      |
| Women's Preventive Services Initiative      |                      |
| recommends that clinicians review a         |                      |
| woman's sexual history and risk factors to  |                      |
| help identify those at an increased risk of |                      |
| STIs. Risk factors include, but are not     |                      |
| limited to, age younger than 25, a recent   |                      |
| history of an STI, a new sex partner,       |                      |
| multiple partners, a partner with           |                      |
| concurrent partners, a partner with an STI, |                      |
| and a lack of or inconsistent condom use.   |                      |
| For adolescents and women not identified    |                      |
| as high risk, counseling to reduce the risk |                      |
| of STIs should be considered, as            |                      |
| determined by clinical judgment.            |                      |
|   |                      |
| Refer also to USPSTF's 'Sexually            |                      |
| Transmitted Infections Behavioral           |                      |
| Counseling' recommendation.                 |                      |

| Urinary Incontinence Screening              | There are no          | Payable with a diagnosis code in |
|---|-----------------------|----------------------------------|
|   | procedure codes       | Diagnosis List 1                 |
| HRSA Recommendation December 2019           | specific to this      |                                  |
| The Women's Preventive Services             | service. This service |                                  |
| Initiative recommends screening women       | would be part of the  |                                  |
| for urinary incontinence annually.          | preventive office     |                                  |
| Screening should ideally assess whether     | visit.                |                                  |
| women experience urinary incontinence       |                       |                                  |
| and whether it impacts                      |                       |                                  |
| their activities and quality of life. The   |                       |                                  |
| Women's Preventive Services Initiative      |                       |                                  |
| recommends referring women for further      |                       |                                  |
| evaluation and treatment if indicated. The  |                       |                                  |
| Women's Preventive Services Initiative      |                       |                                  |
| recommends screening women for urinary      |                       |                                  |
| incontinence as a preventive service.       |                       |                                  |
| Factors associated with an increased risk   |                       |                                  |
| for urinary incontinence include increasing |                       |                                  |
| parity, advancing age, and obesity;         |                       |                                  |
| however, these factors should not be used   |                       |                                  |
| to limit screening.                         |                       |                                  |
| Several screening tools demonstrate fair    |                       |                                  |
| to high accuracy in identifying urinary     |                       |                                  |
| incontinence in women. Although             |                       |                                  |
| minimum screening intervals are             |                       |                                  |
| unknown, given the prevalence of urinary    |                       |                                  |
| incontinence, the fact that many women      |                       |                                  |
| do not volunteer symptoms, and the          |                       |                                  |
| multiple, frequently changing risk factors  |                       |                                  |
| associated with incontinence, it is         |                       |                                  |
| reasonable to conduct annually.             |                       |                                  |
|   |                       |                                  |

| Well-Woman Visits                             | 99384, 99385, 99386, | Labs administered as part of a    |
|---|----------------------|-----------------------------------|
|   | 99387, 99394,        | normal pregnancy reimbursable     |
| HRSA Recommendation December 2021             | 99395, 99396,        | at the preventive level when      |
| Women's Preventive Services Initiative        | 99397, G0101,        | billed with a pregnancy diagnosis |
| recommends that women receive at least        | G0438, G0439,        |                                   |
| one preventive care visit per year            | 99078, 99401,        |                                   |
| beginning in adolescence and continuing       | 99402, 99403,        |                                   |
| across the lifespan to ensure the provision   | 99404, 99411,        |                                   |
| of all recommended preventive services,       | 99412, 99408,        |                                   |
| including preconception and many              | 99409, G0396,        |                                   |
| services necessary for prenatal and           | G0442, G0443,        |                                   |
| interconception care, are obtained. The       | G0444                |                                   |
| primary purpose of these visits should be     |                      |                                   |
| the delivery and coordination of              |                      |                                   |
| recommended preventive services as            |                      |                                   |
| determined by age and risk factors. These     |                      |                                   |
| services may be completed at a single or      |                      |                                   |
| as part of a series of visits that take place |                      |                                   |
| over time to obtain all necessary services    |                      |                                   |
| depending on a woman's age, health            |                      |                                   |
| status, reproductive health needs,            |                      |                                   |
| pregnancy status, and risk factors. Well-     |                      |                                   |
| women visits also include pre-pregnancy,      |                      |                                   |
| prenatal, postpartum and interpregnancy       |                      |                                   |
| visits.                                       |                      |                                   |

| ACIP Recommendations: |                      |                          |
|-----------------------|----------------------|--------------------------|
| Service:              | Procedure Code(s):   | Additional Reimbursement |
|                       |                      | Criteria:                |
| COVID-19 Vaccine      | After 11/01/2023:    |                          |
|                       | 91318, 91319,        |                          |
|                       | 91320, 91321,        |                          |
|                       | 91322, 91304         |                          |
| DTaP Vaccine          | 90696, 90698, 90700, |                          |
|                       | 90702, 90723         |                          |
|                       |                      |                          |
| Hepatitis A Vaccine   | 90632, 90633, 90634, |                          |
|                       | 90636                |                          |

| Hepatitis B Vaccine                      | 90739, 90740, 90743, | Hepatitis B Vaccination is       |
|--|----------------------|----------------------------------|
|  | 90744, 90746,        | payable at the preventive level  |
|  | 90747, 90748, 90759  | for newborns under 90 days of    |
|  | 50747, 50748, 50755  | age when obtained in the         |
|  |                      |                                  |
|  |                      | inpatient setting from an in-    |
|  | 000017 00000         | network provider                 |
| Haemophilus Influenzae Type B (Hib)      | 90647, 90648         |                                  |
| Vaccine                                  |                      |                                  |
| Human Papillomavirus Vaccine (HPV)       | 90651                | Payable with a diagnosis code in |
|  |                      | Diagnosis List 1                 |
| Influenza Vaccine                        | 90630, 90653, 90654, |                                  |
|  | 90655, 90656,        |                                  |
|  | 90657, 90658,        |                                  |
|  | 90660, 90661,90662,  |                                  |
|  | 90666, 90667,        |                                  |
|  | 90668, 90672,        |                                  |
|  | 90673, 90674,        |                                  |
|  | 90682, 90685,        |                                  |
|  | 90686, 90687,        |                                  |
|  | 90688, 90689,        |                                  |
|  | 90694, 90756 Q2034,  |                                  |
|  | Q2035, Q2036,        |                                  |
|  | Q2037, Q2038,        |                                  |
|  | Q2039                |                                  |
| Measles, Rubella, Congenital Rubella     | 90707                |                                  |
| Syndrome, and Mumps (MMR)                |                      |                                  |
|  |                      |                                  |
| Measles, Mumps, Rubella, and Varicella   | 90710                |                                  |
| (MMRV)                                   |                      |                                  |
| Meningococcal Vaccine                    | 90644, 90733, 90734, |                                  |
| U  | 90619, 90620,        |                                  |
|  | 90621, 90623         |                                  |
| Monkeypox Vaccine                        | 90611                |                                  |
|  |                      |                                  |
| Pneumococcal Vaccine                     | 90670, 90677, 90732, |                                  |
|  | 90671, 90684         |                                  |
| Polio Vaccine                            | 90713                |                                  |
|  | 50715                |                                  |
| Respiratory Syncytial Virus Immunization | 90380, 90381, 90679, |                                  |
| Nespiratory syncytial virus miniumzation | 90678, 90683         |                                  |
|  |                      |                                  |
| Rotavirus Vaccine                        | 90680, 90681         |                                  |

| Tetanus Toxoid, Reduced Diphtheria     | 90714, 90715         |  |
|--|----------------------|--|
| Toxoid and Acellular Pertussis Vaccine |                      |  |
| (Tdap/Td)                              |                      |  |
| Varicella Vaccine                      | 90716                |  |
| Zoster (Shingles) Vaccine              | 90750                |  |
| Immunization Administration            | 90460, 90461, 90471, |  |
|  | 90472, 90473,        |  |
|  | 90474, 90749,        |  |
|  | 90480, 96380, 96381  |  |

| Bright Futures Recommendations:  |                    |  |
|--|--------------------|--|
| Service:   | Procedure Code(s): | Additional Reimbursement<br>Criteria:  |
| Alcohol Use and Drug Use Assessment  | 99408, 99409       | Payable with a diagnosis code in Diagnosis List 1  |
| Bright Futures   |                    |  |
| Recommends alcohol and drug use  |                    |  |
| assessments for adolescents between the                                    |                    |  |
| ages of 11 to 21 years.  |                    |  |
| Anemia Screening in Children   | 85014, 85018       | Payable with a diagnosis code in   |
| Dright Futures   |                    | Diagnosis List 1   |
| Bright Futures   |                    |  |
| Recommends anemia screening for children under the age of 21 years of age. |                    | For details about pharmacy   |
|  |                    | benefit coverage, contact the<br>number on the patient's BCBS<br>member card. A patient's<br>pharmacy benefit may be<br>managed by a company other<br>than BCBS. |
|  |                    | Prescription required for both<br>OTC and prescription<br>medications. Coverage provided<br>for members up to 1 year of age.                                     |

| Cervical Dysplasia Screening               | Q0091                | Payable with a diagnosis code in                  |
|--|----------------------|---|
| Dricht Futures                             |                      | Diagnosis List 1                                  |
| Bright Futures                             |                      |   |
| Recommends cervical dysplasia screening    |                      |   |
| for adolescents age 21 years of age        |                      |   |
| Critical Congenital Heart Defect Screening | 94760                |   |
| Bright Futures                             |                      |   |
| Recommends screening for critical          |                      |   |
| congenital heart disease using pulse       |                      |   |
| oximetry for newborns after 24 hours of    |                      |   |
| age, before discharge from the hospital    |                      |   |
| Depression Screening                       | 96127                | Payable with a diagnosis code in Diagnosis List 1 |
| Bright Futures                             |                      |   |
| Recommends depression screening for        |                      |   |
| adolescents between the ages of 11 to 21   |                      |   |
| years                                      |                      |   |
| Refer also to USPSTF's 'Depression in      |                      |   |
| Children and Adolescents Screening'        |                      |   |
| recommendation                             |                      |   |
| Developmental Screening / Autism           | 96110                | Payable with a diagnosis code in                  |
| Screening                                  |                      | Diagnosis List 1                                  |
| Bright Futures                             |                      |   |
| Recommends developmental/autism            |                      |   |
| screening for infants and young children   |                      |   |
| between the ages of 9 months and 30        |                      |   |
| months                                     |                      |   |
| Dyslipidemia Screening                     | 80061, 82465, 83718, | Payable with a diagnosis code in                  |
|  | 84478                | Diagnosis List 1                                  |
| Bright Futures                             |                      |   |
| Recommends dyslipidemia screening for      |                      |   |
| children and adolescents between the       |                      |   |
| ages of 24 months and 21 years of age      |                      |   |
|  |                      |   |

| Hearing Screening                        | 92558, 92567, 92551, | Procedure codes 92558, 92567,     |
|--|----------------------|-----------------------------------|
|  | 92650, 92651,        | 92551, V5008 are payable at the   |
| Bright Futures                           | 92652, 92653, V5008  | preventive level only when billed |
| Recommends hearing screenings for        |                      | with diagnosis codes Z01.10,      |
| children and adolescents from birth      |                      | Z01.118, and Z01.110 for ages 22  |
| through 21 years of age                  |                      | and under.                        |
|  |                      |                                   |
|  |                      | Eff. 01/01/2021 CPT codes         |
|  |                      | 92650, 92651, 92652, 92653        |
|  |                      | may be payable at the             |
|  |                      | preventive level only when billed |
|  |                      | with diagnosis codes Z01.10,      |
|  |                      | Z01.118, and Z01.11 through       |
|  |                      | ages 22 and under if meeting      |
|  |                      | Medical Policy criteria.          |
| Hematocrit or Hemoglobin                 | 36415, 36416, 85014, | Payable with a diagnosis code in  |
|  | 85018                | Diagnosis List 1                  |
| Bright Futures                           |                      |                                   |
| Recommends hematocrit or hemoglobin      |                      |                                   |
| screening for children and adolescents   |                      |                                   |
| between the ages of four months and 21   |                      |                                   |
| years of age                             |                      |                                   |
| HIV Screening                            | 87389, 87390, 87391, | Payable with a diagnosis code in  |
|  | 87806, G0432,        | Diagnosis List 1                  |
|  | G0433, G0435         |                                   |
|  |                      |                                   |
| Lead Screening                           | 36415, 36416, 83655  | Payable with a diagnosis code in  |
|  |                      | Diagnosis List 1                  |
| Bright Futures                           |                      |                                   |
| Recommends screening children between    |                      |                                   |
| the ages of six months and six years for |                      |                                   |
| lead                                     |                      |                                   |
| Maternal Depression Screening            | 99384, 99385, 99386, |                                   |
|  | 99387, 99394,        |                                   |
|  | 99395, 99396,        |                                   |
|  | 99397, G0444         |                                   |
| Newborn Bilirubin                        | 82247, 82248, 88720  | Payable with a diagnosis code in  |
|  |                      | Diagnosis List 1                  |
| Newborn Blood Screening                  | S3620                | Payable with a diagnosis code in  |
|  |                      | Diagnosis List 1                  |

| Oral Health                                | 99211, 99212, 99188, | Payable with a diagnosis code in                     |
|--|----------------------|--|
|  | 99381, 99382,        | Diagnosis List 1                                     |
| Bright Futures                             | 99383, 99384         |  |
| Recommends oral health risk assessments    |                      |  |
| beginning at six months of age             |                      |  |
|  |                      |  |
| Prenatal Visit                             | 99401, 99402, 99403, | Payable with a diagnosis code in                     |
|  | 99404                | Diagnosis List 1                                     |
| Preventive Medicine Services: New          | 99381, 99382, 99383, | Payable with a diagnosis code in                     |
| Patients                                   | 99384, 99385         | Diagnosis List 1                                     |
|  |                      |  |
| Preventive Medicine Services: Established  | 99391, 99392, 99393, | Payable with a diagnosis code in                     |
| Patients                                   | 99394, 99395         | Diagnosis List 1                                     |
|  |                      |  |
| STI/HIV Screening                          | 86631, 86632, 86701, | Payable with a diagnosis code in                     |
|  | 86703, 87081,        | Diagnosis List 1                                     |
| Bright Futures                             | 87110, 87210,        |  |
| Recommends screening for all sexually      | 87270, 87320,        |  |
| active patients                            | 87490, 87491,        |  |
|  | 87590, 87591,        |  |
| Refer also to USPSTF's 'Human              | 87800, 87801,        |  |
| Immunodeficiency Virus (HIV) Infection     | 87810, 87850, 36415  |  |
| Screening for Pregnant and Non-Pregnant    |                      |  |
| Adolescents and Adults' recommendations    |                      |  |
| Refer also to HRSA's 'Sexually Transmitted |                      |  |
| Infections Counseling' recommendation      |                      |  |
| Tuberculosis Testing                       | 86580, 99211         | Payable with a diagnosis code in                     |
|  |                      | Diagnosis List 1                                     |
| Bright Futures                             |                      |  |
| Recommends tuberculosis testing if the     |                      |  |
| risk assessment is positive                |                      |  |
| Vision Scrooning                           | 99173                | Davable with a diagnosis code in                     |
| Vision Screening                           | 2112                 | Payable with a diagnosis code in<br>Diagnosis List 1 |
| Bright Futures                             |                      | LIGE T   |
| Recommends vision screening for            |                      |  |
| newborns through age 21 years              |                      |  |
|  |                      |  |
|  |                      |  |

Many of the services listed above may be performed for indications other than preventive care. In these situations, services may be covered by another provision of the individual's benefit plan and subject to applicable cost sharing.

| Z00.00  | Z00.01  | Z00.110 | Z00.111 | Z00.121 | Z00.129 | Z00.8   |
|---------|---------|---------|---------|---------|---------|---------|
| Z01.411 | Z01.419 | Z02.83  | Z11.1   | Z11.3   | Z11.4   | Z11.51  |
| Z11.7   | Z12.11  | Z12.12  | Z12.2   | Z12.31  | Z12.39  | Z12.4   |
| Z12.5   | Z13.0   | Z13.1   | Z13.220 | Z13.31  | Z13.32  | Z13.40  |
| Z13.41  | Z13.42  | Z13.5   | Z13.6   | Z13.820 | Z20.2   | Z20.6   |
| Z23     | Z30.011 | Z30.012 | Z30.013 | Z30.014 | Z30.015 | Z30.016 |
| Z30.017 | Z30.018 | Z30.019 | Z30.02  | Z30.09  | Z30.40  | Z30.41  |
| Z30.42  | Z30.430 | Z30.431 | Z30.432 | Z30.433 | Z30.44  | Z30.45  |
| Z30.46  | Z30.49  | Z30.8   | Z30.9   | Z32.2   | Z71.41  | Z71.51  |
| Z71.6   | Z71.7   | Z71.82  | Z71.83  | Z86.32  | Z97.5   | R73.03  |

#### Diagnosis List 1

#### Breastfeeding Equipment & Supplies

Non-grandfathered plans provide coverage of manual, electric, and hospital grade breast pumps along with breastfeeding supplies at the preventive level.

**Manual breast pumps** utilize procedure code E0602 and are available for purchase and covered at the preventive level when obtained In-Network, Out of Network, or from Retail providers. Sales tax is excluded from retail purchases.

**Electric breast pumps** utilize procedure code E0603 and must be rented or purchased from an InNetwork provider or a contracted durable medical equipment supplier. The models of breast pumps being provided at the preventive level are up to the individual provider's discretion. If a member chooses to obtain an upgraded model, they may be balance billed the difference between the allowance of the standard model and the cost of the upgraded model. Members are allowed one electric breast pump per benefit period.

\*Note: Retail providers such as Target, Wal-Mart, or online vendor are not licensed medical providers and therefore are considered Out of Network. Out of network coverage will follow the out of network benefit level for preventive services. This may include cost sharing and sales tax is excluded. \*

**Hospital grade breast pumps** utilize procedure code E0604 and are only covered when rented InNetwork or from an In-Network durable medical equipment supplier. Hospital grade breast pump coverage is up to the purchase price of \$1,000.00 or 12 months, whichever comes first. At the end of coverage, the unit must be returned to the durable medical equipment supplier. Members are allowed one breast pump per benefit period.

Breast pumps obtained from Out of Network providers are reimbursable at the Out of Network level.

The following breast pump supplies are reimbursable at the preventive level. Some limitations and restrictions may apply based on the group coverage for preventive services.

- A4281- Tubing for breast pump, replacement, spare membranes, replacements
- A4282- Adapter for breast pump, replacement
- A4283- Cap for breast pump bottle, replacement
- A4284- Breast shield and splash protector for use with breast pump, replacement
- A4285- Polycarbonate bottle for use with breast pump, replacement
- A4286- Locking ring for breast pump, replacement

#### Differentiating Preventive Care versus Diagnostic Care

The following types of services are considered Preventive:

- Screenings intended to prevent illness or identify issues before symptoms are evident
- Counseling intervention as defined by a specific preventive recommendation

#### Examples of preventive services:

- A 60-year-old woman obtains her biennial mammogram to screen for breast cancer
- A patient who has been identified as having cardiovascular disease risk factors is referred for nutritional counseling
- A 50-year-old patient obtains a colonoscopy to screen for colorectal cancer
- A 42-year-old patient goes to their doctor for their annual physical and receives a blood test to screen for abnormal blood glucose

The following types of services are considered Diagnostic:

- The diagnosis of existing symptoms or abnormalities
- Treatment for specific health conditions, ongoing care, or other tests to manage a health condition

Examples of diagnostic services:

- A 60-year-old woman obtains a mammogram after noticing a lump in her breast
- A patient diagnosed with diabetes is referred for nutritional counseling to manage their condition
- A patient goes to their doctor for their annual physical and receives a blood test to check iron and liver function, and a urinalysis is requested

#### Limitations and Exclusions

- 1. <u>Services not reimbursable at the preventive level may be reimbursable under another portion of the medical plan.</u>
- 2. Breastfeeding equipment and supplies not listed underneath the "Breastfeeding Equipment and Supplies" section. This includes, but is not limited to

- a. Batteries
- b. Breastfeeding ointments, creams
- c. Breast milk storage supplies including bags, freezer packs, etc.
- d. Breast pump cleaning supplies
- e. Breast pump traveling cases
- f. Infant scales
- g. Nursing bras
- h. Nursing covers, scarfs
- 3. Immunizations that are not published in the Center for Disease Control's Morbidity and Mortality Weekly Report (MMWR) and/or are not on the list of "Vaccines Licensed for Use in the United States" by the United States Food and Drug Administration (FDA).
- 4. Prescription coverage may vary depending on the terms and conditions of the plans. A prescription may be required for coverage under the pharmacy benefit. The plan may also require that the generic drug be tried first before the brand version. Age limits, restrictions, and other requirements may apply. Members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 5. For OTC purchases, members will need to obtain a prescription from their provider and take it to the pharmacy to be filled.
- 6. Exceptions may apply, members can verify their pharmacy benefits by calling the customer service number on the back of their ID card.
- 7. If there is a medication not included, the member should consult their doctor for therapeutic alternatives first before submitting coverage exceptions to BCBS.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a MEDICAL POLICY and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.

## References

Advisory Committee on Immunization Practices (ACIP). "Vaccine-Specific ACIP Recommendations." Retrieved March 1, 2022, from <u>https://www.cdc.gov/vaccines/hcp/acip-recs/index.html</u>

American Academy of Pediatrics- Bright Futures. "Coding for Pediatric Preventive Care, 2022." Retrieved March 16, 2023, from

https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf?\_ga=2.94179101.1664058044. 1678994595-714521604.1673643544

American Academy of Pediatrics - Bright Futures. "Recommendations for Preventive Pediatric Health Care." Retrieved March 1, 2023, from

https://publications.aap.org/pediatrics/article/150/1/e2022058044/188302/2022-Recommendationshttps://publications.aap.org/pediatrics/article/150/1/e2022058044/188302/2022-Recommendations-for-Preventive-Pediatric?\_ga=2.129116298.748527027.1677624224-1461735393.1677624222?autologincheck=redirectedfor-Preventive-Pediatric?\_ga=2.129116298.748527027.1677624224-1461735393.1677624222?autologincheck=redirected

American Academy of Pediatrics- Bright Futures. "Achieving Bright Futures." Retrieved March 16, 2023, from <u>https://downloads.aap.org/AAP/PDF/periodicity\_schedule.pdf?\_ga=2.170328992.1664058044.1678994 595-714521604.1673643544</u>

Centers for Disease Control and Prevention. "Immunization Schedules." Retrieved March 1, 2022, from <u>https://www.cdc.gov/vaccines/schedules/index.html</u>

Health Resources and Services Administration. "Women's Preventive Services Guidelines." Retrieved December 15th, 2022, from <u>https://www.hrsa.gov/womens-guidelines</u>

United States Food and Drug Administration. "Vaccines Licensed for Use in the United States." Retrieved March 1, 2022,

https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833

United States Preventive Services Task Force. "Published Recommendations." Retrieved March

1, 2022, from

https://www.uspreventiveservicestaskforce.org/BrowseRec/Index/browse-recommendations

## **Policy Update History**

| Approval Date | Description                                     |
|---------------|---|
| 06/23/2017    | New policy, replaces medical policy ADM1001.030 |
| 07/14/2017    | Removed codes 99174 and 99177.                  |
| 12/06/2017    | Coding and USPSTF updates                       |
| 04/30/2018    | Coding and USPSTF updates                       |
| 07/12/2018    | Coding and USPSTF updates                       |
| 12/27/2018    | Coding and USPSTF updates                       |
| 09/26/2019    | Coding and USPSTF updates                       |
| 10/14/2019    | HPV vaccine update                              |

| 12/30/2019 | Disclaimer, Coding and USPSTF updates                                       |
|------------|---|
| 04/20/2020 | Recommendation updates  |
| 06/08/2020 | Disclaimer, Coding, Links, and recommendation updates                       |
| 09/09/2020 | Coding and recommendation updates   |
| 12/21/2020 | Coding and recommendation updates, drug information updates and disclaimers |
| 01/12/2021 | Coding updates  |
| 09/22/2021 | Coding and recommendation updates, drug information updates                 |
| 12/16/2021 | Coding and USPSTF updates   |
| 03/23/2022 | Coding and recommendation updates   |
| 06/01/2022 | Coding and recommendation updates   |
| 07/29/2022 | Diagnosis List 1 updates  |
| 09/09/2022 | Coding and recommendation updates   |
| 02/20/2023 | Coding updates  |
| 03/16/2023 | Coding and recommendation updates, hyperlink updates                        |
| 5/24/2023  | Coding and recommendation updates   |
| 06/01/2023 | Coding and recommendation updates   |
| 09/25/2023 | Coding and recommendation updates   |
| 09/27/2023 | Coding and recommendation updates   |
| 12/18/2023 | Coding and recommendation updates   |
| 3/22/2024  | Coding and recommendation updates   |
| 06/01/2024 | Coding and recommendation updates   |
| 08/29/2024 | Coding and recommendation updates   |

The Plan makes no endorsement, representations or warranties regarding any products or services offered by independent third-party vendors such as Target and Wal-Mart. These vendors are solely responsible for the products and services they offer. If you have any questions about the products or services offered by such vendors, you should contact the vendor(s) directly.